EUCTR2004-005210-37-FI
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.
ConditionsRheumatoid Arthritis
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- F. Hoffmann La-Roche AG
- Enrollment
- 1,200
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1\.Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2\.Patients with rheumatoid arthritis of ³ 6 months duration diagnosed according to the revised 1987 American College of Rheumatology (ACR; formerly American Rheumatism Association) criteria (Appendix 2\).
- •3\.Receiving treatment on an outpatient basis.
- •4\.Prior to randomization, will have discontinued etanercept for ³ 2 weeks, infliximab or adalimumab for ³ 8 weeks (see exclusion \# 5\), anakinra for ³ 1 week.
- •5\.Have received permitted DMARDs, each at a stable dose, for at least 8 weeks prior to baseline.
- •6\.Swollen joint count (SJC) ³ 6 (66 joint count) and tender joint count (TJC) ³ 8 (68 joint count) at screening and baseline.
- •7\.At screening either CRP ³ 1 mg/dL (10 mg/L) or ESR ³ 28 mm/hr
- •8\.Age ³ 18 years
- •9\.Oral corticosteroids (£ 10 mg/day prednisone or equivalent) and NSAIDs (up to the maximum recommended dose) are permitted if the dose has been stable for at least 6 weeks prior to baseline.
- •10\.Females of child\-bearing potential and males with female partners of child\-bearing potential may participate in this trial only if using a reliable means of contraception (e.g. physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or IUD).
Exclusion Criteria
- •1\.Major surgery (including joint surgery) within eight weeks prior to screening or planned surgery within six months following randomization.
- •2\.Rheumatic autoimmune disease other than RA, including SLE, MCTD, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Sjögren’s Syndrome with RA is allowable.
- •3\.Functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
- •4\.Prior history of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease).
- •Excluded Previous or Concomitant Therapy:
- •5\.Unsuccessful treatment with an anti\-TNF agent (i.e. significant safety issues or lack of efficacy; Patients who terminated previous anti\-TNF treatment due to cost or discomfort with the subcutaneous injections, may participate in this study.) (See Inclusion \#4 for anti\-TNF agent washouts.)
- •6\.Treatment with any investigational agent within four weeks (or five half\-lives, whichever is longer) of screening.
- •7\.Previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti\-CD4, anti\-CD5, anti\-CD3, anti\-CD19 and anti\-CD20\).
- •8\.Treatment with intravenous gamma globulin, plasmapheresis or Prosorba ä column within six months of baseline.
- •9\.Intra\-articular or parenteral corticosteroids within six weeks prior to baseline.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
Active, not recruiting
Not Applicable
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
Active, not recruiting
Phase 1
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200